DocWire News Editors

DocwireNews

The triple combination of carflizomib, pomalidomide, and dexamethasone (KPd) is an effective, and well-tolerated option for patients with relapsed and/or refractory multiple myeloma (RRMM), according to a study presented at the 17th International Myeloma Workshop.
In this study, researchers combined data from two single-arm studies and analyzed 183 patients. In both studies, patients were administered KPd in 28-day cycles with treatment continued until disease progression or unacceptable toxicity. The primary outcome was to estimate the overall response rate of KPd (ORR) and secondary endpoints were specified as the assessment of progression-free survival (PFS), overall survival (OS), and safety.
The findings showed that the average number of prior lines of therapy in the pooled population was 4 (range, 1–15), and the ORR for the individual studies was 77% and 70%, respectively with a pooled rate of 73% (95% CI, 67 to 79). The researchers observed that the pooled proportion of patients who had very good partial response or better was 35% (95% CI, 28 to 42), and the average OS was 29.6 months (95% CI, 26 to 34), and 12 and 24-month PFS rates were 49% and 20%, respectively in the population of interest. Overall, the study showed that 78% of patients reported at least one grade 3 or 4 treatment-emergent adverse event (TEAE), with the frequency of grade TEAEs grade 3 or greater in the pooled KPd population consistent with other carflizomib dosing regimens.
“As the need for lenalidomide sparing regimens is increasing, KPd is an important, effective, and well-tolerated option for lenalidomide exposed patients in both early and later relapse settings,” the authors wrote. “Future research should assess these promising results against sound clinical benchmarks.”
Jakubowiak A, et al. Efficacy and Safety of Carflizomib-Pomalidomide-Dexamethasone in Relapsed and/or Refractory Multiple Myeloma: Pooled Analysis of 2 Single Arm Studies. Presented at the 17th International Myeloma Workshop; September 12-15, 2019; Boston, MA.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Efficacy and Safety of Carfilzomib Pomalidomide-Dexamethasone in Relapsed and/or Refractory Multiple Myeloma: Pooled Analysis of 2 Single Arm Studies

International Myeloma Workshop 2019

The triple combination of carflizomib, pomalidomide, and dexamethasone (KPd) is an effective, and well-tolerated option for patients with relapsed and/or refractory multiple ...

Efficacy and Safety of Carfilzomib Pomalidomide-Dexamethasone in Relapsed and/or Refractory Multiple

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe